ADVA
4.6.2020 09:02:08 CEST | Business Wire | Press release
ADVA (FSE: ADV) today launched the industry’s first ePRC optical cesium atomic clock solution, protecting synchronization networks from costly and dangerous interruptions to satellite signals. The Oscilloquartz OSA 3350 ePRC+ provides unprecedented stability and significantly longer lifetime compared to all other ePRC cesium clocks. It’s also the first cesium clock on the market with built-in SNMP support. This innovation in the design of atomic clocks comes at a critical time when GNSS outages caused by jamming and spoofing attacks are on the rise. Long GNSS disruptions can cause severe network outages and so the OSA 3350 ePRC+ offers vital backup for mission-critical infrastructures that depend on satellite-based timing, such as mobile networks and power utilities. The OSA 3350 ePRC+ also meets the stringent performance demands as well as the cost points needed for mobile networks transitioning to 5G.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200604005036/en/
“Our OSA 3350 ePRC+ is a truly unique achievement and its importance to the industry can’t be overstated. It arrives at a crucial time with operators seeking an efficient way to deliver highly accurate, ultra-stable frequency and phase synchronization with significantly longer lifetime than existing cesium clocks. Now they can mitigate GNSS vulnerabilities by harnessing market-leading holdover performance for the most robust backup available,” said Gil Biran, general manager, Oscilloquartz, ADVA. “Creating a viable commercial optical atomic clock has been a key mission for a long time. By achieving it, we’re making sure that communication service providers never again have to compromise between performance and lifetime. And, with a frequency stability that outperforms current ITU-T ePRC G.811.1 standards, our OSA 3350 ePRC+ provides the safety net needed for 5G networks.”
Featuring an all-digital design, the OSA 3350 ePRC+ leverages optical-pumping techniques. It greatly improves performance by providing an extremely stable frequency source. When used with enhanced primary reference time clocks (ePRTCs), the OSA 3350 ePRC+ delivers holdover for 14 days with an accumulated error of up to 35 nanoseconds. This far exceeds the ITU-T ePRC G.811.1 standard that requires an accumulated error under 70 nanoseconds. The OSA 3350 ePRC+ also delivers optimum stability for over 10 years, which is 100% longer than the lifespan of high-performance magnetic cesium clocks. With a fully modular design, the optical cesium solution features a wide range of telecom synchronization output interfaces and supports modern and secured management capabilities with SNMP. What’s more, the RoHS-compliant device is fully integrated into ADVA’s Ensemble management and control software suite for operational simplicity and ease of use.
“With our OSA 3350 ePRC+, we’re providing a critical component of tomorrow’s network synchronization. For decades, engineers have focused on maximizing the performance of magnetic cesium clocks despite their limitations. Now we’re opening up a new chapter in the history of time and frequency delivery with a technology that optimizes both performance and lifetime,” commented Nir Laufer, senior director, product line management, Oscilloquartz, ADVA. “The incredible stability and accuracy that our OSA 3350 ePRC+ generates will bring essential improvements needed for 5G and other critical infrastructures deriving timing from GNSS. At a time when jamming and spoofing attacks are increasing in frequency and duration, it offers vital backup to satellite-based timing. Our OSA 3350 ePRC+ is also fully integrated into our Ensemble network management software suite with built-in SNMP. It couldn’t be easier to monitor the health of the device and perform software upgrades remotely at the touch of the button.”
Watch this product video for more information: https://youtu.be/8jk4y6kH0Ug .
A supporting application video is available here: https://youtu.be/VarsNZNQB9w .
Further details can also be found in these slides: https://adva.li/osa-3350-slides .
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we're creating new opportunities for tomorrow's networks. For more information, please visit us at www.oscilloquartz.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
View source version on businesswire.com: https://www.businesswire.com/news/home/20200604005036/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
